Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Каталог · ЕАЭС

Клинические исследования и проекты

Новартис Фарма АГ · найдено 453

Ищем по всем вариантам написания в реестрах, по-русски и по-английски. Спонсор или разработчик.
Статус
Что исследуют
Источник
Фаза
Страна
Участники
Кто может участвовать По критериям ClinicalTrials.gov. Исследования, где реестр возраст и пол не указывает, тоже показываются. Возраст и пол нигде не сохраняются.
Сбросить
453 исследования
Завершено Фаза II Россия
QAX576; Placebo · Новартис Фарма АГ

A Multi-center, Randomized, Double Blind, Placebo-controlled, 'add-on' Study to Investigate the Efficacy and Safety of 24 Weeks Intravenous Treatment With QAX576 in Patients (≥18-75 Years) With Persistent Asthma Not Adequately Controlled With Inhaled Corticosteroids and Long Acting β2-agonists

259 участников во всех странах ClinicalTrials.gov CQAX576A2207
Завершено Фаза IV Россия
CLAF237ARU05 · Новартис Фарма АГ

Interventional Study of Active Weight Management in Patients With Type 2 Diabetes and Obesity in Routine Clinical Practice During 12 Months.

130 участников во всех странах ClinicalTrials.gov CLAF237ARU05
Завершено Фаза III Россия
Pasireotide; Octreotide · Новартис Фарма АГ

A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly

358 участников во всех странах ClinicalTrials.gov CSOM230C2305
Завершено Фаза II Россия
LCZ696 · Новартис Фарма АГ

An Open Label, Non-randomised Study to Explore Safety/Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 in Patients With Stable Heart Failure

Москва 1 центр 30 участников во всех странах ClinicalTrials.gov CLCZ696A2117
Завершено Фаза IV Россия
Everolimus · Новартис Фарма АГ

Long-term Follow-up Study to Monitor the Growth and Development of Pediatric Patients Previously Treated With Everolimus in Study CRAD001M2301 (EXIST-LT)

15 участников во всех странах ClinicalTrials.gov CRAD001M2305
Завершено Фаза III Россия
Canakinumab 150 mg; Triamcinolone acetonide 40 mg; Placebo to canakinumab; Placebo to triamcinolone acetonide · Новартис Фарма АГ

A Randomized, Controlled Study of ACZ885 (Canakinumab) on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective Including a 12 Weeks Extension Study and a 1 Year Open-label Extension Study

226 участников во всех странах ClinicalTrials.gov CACZ885H2357
Завершено Фаза III Россия
Tobramycin inhalation powder · Новартис Фарма АГ

A Phase III Open-Label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder After Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Subjects Who Completed Participation in Study CTBM100C2303.

55 участников во всех странах ClinicalTrials.gov CTBM100C2303E1
Прекращено Фаза II Россия
QAV680; QAV680 Placebo · Новартис Фарма АГ

A Randomized, Double-blind, Parallel Group Study to Compare the Pharmacodynamics/Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With Moderate Persistent Asthma

8 участников во всех странах ClinicalTrials.gov CQAV680A2201E1
Завершено Фаза III Россия
Tacrolimus (reduced tacrolimus); Everolimus (reduced tacrolimus); Tacrolimus (tacrolimus elimination); Everolimus (tacrolimus elimination); Tacrolimus (tacrolimus control); Corticosteroids · Новартис Фарма АГ

Extension Study to the Multicenter, Open-label, Randomized, Controlled Study CRAD001H2304 to Evaluate the Long-term Efficacy and Safety of Concentration-controlled Everolimus in Liver Transplant Recipient

284 участника во всех странах ClinicalTrials.gov CRAD001H2304E1
Завершено Россия
CLCZ696B3402 · Новартис Фарма АГ

A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care

1 415 участников во всех странах ClinicalTrials.gov CLCZ696B3402
Завершено Фаза III Россия
Daptomycin; Vancomycin or Semi-Synthetic Penicillins (SSPs) · Новартис Фарма АГ

An Open Label, Multi-center, Randomized, Comparative Phase IIIb Study to Compare Efficacy and Safety of Intravenous (i.v.) Daptomycin With That of Semi-Synthetic Penicillins (SSPs) or Vancomycin in the Treatment of Elderly Patients (Aged ≥ 65 Years) With Complicated Skin and Soft Tissue Infections (cSSTI)

120 участников во всех странах ClinicalTrials.gov CCBC134A2404
Завершено Фаза II Россия
LCZ696; Valsartan; AHU377; Placebo · Новартис Фарма АГ

A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension

1 334 участника во всех странах ClinicalTrials.gov CLCZ696A2201
Завершено Фаза II Россия
Canakinumab · Новартис Фарма АГ

A 24-week Open-label, Multicenter, Follow-up and Extension Study to CACZ885H2251, to Assess Safety, Tolerability and Efficacy of Canakinumab (ACZ885) in Patients With Gout Who Were Given Canakinumab at the Time of Gout Flare

341 участник во всех странах ClinicalTrials.gov CACZ885H2251E1
Завершено Фаза III Россия
Dabrafenib; Vemurafenib; Trametinib · Новартис Фарма АГ

A Phase III, Randomised, Open-label Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to the BRAF Inhibitor Vemurafenib in Subjects With Unresectable (Stage IIIc) or Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma

704 участника во всех странах ClinicalTrials.gov 116513
Идёт Россия
Ribociclib; Letrozole; Anastrozole · Новартис Фарма АГ

Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice

240 участников во всех странах ClinicalTrials.gov CLEE011O1RU01
Завершено Фаза IV Россия
RAD001 · Новартис Фарма АГ

An Open-label, Multi-center Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for Patients With Metastatic Recurrent and/or Unresectable Renal Cell Carcinoma (EVERMORE).

143 участника во всех странах ClinicalTrials.gov CRAD001LIC01
Завершено Фаза II Россия
RAD001(everolimus); interferon alfa-2a; bevacizumab · Новартис Фарма АГ

A Randomized, Open-label, Multi-center Phase II Study to Compare Bevacizumab Plus RAD001 Versus Interferon Alfa-2a Plus Bevacizumab for the First-line Treatment of Patients With Metastatic Clear Cell Carcinoma of the Kidney

365 участников во всех странах ClinicalTrials.gov CRAD001L2201
Завершено Фаза III Россия
vildagliptin; Placebo · Новартис Фарма АГ

A 28 Week Extension to a 24 Week Multi-center, Randomized, Double-blind Clinical Trial to Evaluate the Safety and Tolerability of Vildagliptin (50 mg qd) Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency

Москва, Санкт-Петербург и ещё 3 города 10 центров 349 участников во всех странах ClinicalTrials.gov CLAF237A23137E1
Завершено Фаза III Россия
FTY720 · Новартис Фарма АГ

A 4-month, Open-label, Multi-center Study to Explore Tolerability and Safety and Health Outcomes of FTY720 in Patients With Relapsing Forms of Multiple Sclerosis

2 417 участников во всех странах ClinicalTrials.gov CFTY720D2316
Завершено Фаза III Россия
Tacrolimus (reduced tacrolimus); Tacrolimus (tacrolimus elimination); Tacrolimus (tacrolimus control); Everolimus (reduced tacrolimus); Everolimus (tacrolimus elimination); Corticosteroids · Новартис Фарма АГ

A 24 Month, Multicenter, Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients

719 участников во всех странах ClinicalTrials.gov CRAD001H2304

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.